Tuberculosis (TB) is one of the commonest opportunistic infections in kidney transplant recipients and can have diverse clinical presentations leading to a delay in the diagnosis. We evaluated risk factors, clinical presentation, impact of TB on patient, and the graft outcomes. We studied 703 kidney transplant recipients from 1985-2018 at a tertiary care centre in western India. Demographic details, past history of TB, immunosuppression regimens, time to diagnosis of tuberculosis post-transplant, clinical presentations, duration of treatment, adverse effects of treatment, and its outcome on patient and graft were studied. Tuberculosis was diagnosed in 103 recipients (14.6%) post-transplant. The mean (SD) age of recipients was 35.12±10 years, with 93 (90.2%) being males and 102 recipients (99.1%) from a living donor. Nineteen recipients (18.4%) had tuberculosis before transplant. The median (IQR) time to diagnosis of TB post-transplant was 24 months (8-48). In 41(39.8%) recipients, development of tuberculosis was preceded by anti-rejection therapies. Pulmonary involvement was the most common organ involvement in 72 recipients (69.9%), extrapulmonary in 31 (30%) and disseminated in 2 (1.9%). Among the extrapulmonary involvements, gastrointestinal involvement was seen in 9 recipients (8.7%) followed by musculoskeletal in 7(6.8%), lymphadenitis in 6 (5.8%), central nervous system in 3 (2.9%), cutaneous involvement in 2 (1.9%), genitourinary TB in 1 (0.9%) and transplant kidney in 1 (0.9%). The median (IQR) duration of treatment was 12 months (5-18). Four recipients had relapses after completion of treatment. Adverse effects of treatment included transaminase elevation seen in 38 (38.6%) recipients followed by acute gastritis in 19 (18.4%), hyperuricemia in 17 (16.5%) and sensorineural hearing loss in 3 (2.9%). Multidrug-resistant TB was diagnosed in 3 recipients (2.9%). The pre-transplant median (IQR) dialysis vintage was 8 months (6-12). New onset diabetes after transplant was the most common comorbidity observed in 28 (27.18%) recipients, followed by Hepatitis C in 16 (15.55%), Hepatitis B in 12 (11.6 %), Cytomegalovirus (CMV) in 6(5.8%) and HIV in 2 recipients (1.9%). Immunosuppressive regimens at time of transplant included azathioprine in 61 recipients (59.2%), mycophenolate mofetil in 40(38.8%), tacrolimus in 38(36.8%), cyclosporine in 26(25.2%) and steroids in 103(100%) recipients. Acute graft dysfunction during treatment was seen in 42 recipients (40.7%). Three recipients (2.9%) developed graft failure. Seventy-two recipients (69.9%) survived after treatment, 16 (15.5%) expired due to TB, and 15(14.5%) were lost to follow-up. Tuberculosis remains a common infectious complication after kidney transplant and is associated with significant morbidity and mortality.